Prot #0113-CL-1004: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell

Project: Research project

Project Details

StatusFinished
Effective start/end date8/29/14 → 8/29/17

Funding

  • CTI Clinical Trial and Consulting Services (Prot #0113-CL-1004 // Prot #0113-CL-1004)
  • Astellas Pharma Global Development, Inc. (Prot #0113-CL-1004 // Prot #0113-CL-1004)